Meeting
2023 ASCO Annual Meeting
CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer.
Authors
Peter A. Fasching
Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Peter A. Fasching , Sara Brucker , Hanna Huebner , Verena Thewes , Lea Louise Volmer , Andreas Daniel Hartkopf , Hans-Christian Kolberg , Benno Lex , Bahriye Aktas , Nina Ditsch , Lothar Haeberle , Katharina Seitz , Daniel Anetsberger , Naiba Nabieva , Christian Roos , Erik Belleville , Andreas Schneeweiss , Volkmar Mueller , Wolfgang Janni , Tanja N. Fehm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT05452213
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS1124)
DOI
10.1200/JCO.2023.41.16_suppl.TPS1124
Abstract #
TPS1124
Poster Bd #
338b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.
First Author: Laura Sabina Lapuchesky
Poster
2018 ASCO Annual Meeting
First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.
First Author: Gabriel N. Hortobagyi
Poster
2017 ASCO Annual Meeting
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).
First Author: Gabriel N. Hortobagyi
Poster
2019 ASCO Annual Meeting
First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.
First Author: Joyce O'Shaughnessy